دورية أكاديمية
CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy
| العنوان: | CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy |
|---|---|
| المؤلفون: | Mazzuca, Federica, Botticelli, Andrea, Mazzotti, Eva, La Torre, Marco, Borro, Marina, Marchetti, Luca, Maddalena, Chiara, Gentile, Giovanna, Simmaco, Maurizio, Marchetti, Paolo |
| بيانات النشر: | AVES |
| سنة النشر: | 2016 |
| المجموعة: | Acibadem University Repository |
| مصطلحات موضوعية: | Adjuvant hormonal therapy, rs4646, aromatase inhibitor, breast cancer, CYP19A1, single nucleotide polymorphisms |
| الوصف: | Objective: Third-generation aromatase inhibitors (AI) are potent suppressors of aromatase activity. The aim of this study was to measure the incidence of adverse effects in breast cancer patients treated with AI-based adjuvant therapy and the relationship with the CYP19A1 genotypes. Materials and Methods: Forty-five postmenopausal breast cancer patients (46-85 yrs) in AI adjuvant treatment were genotyped for the rs4646 polymorphisms of CYP19A1 gene and three variations were identified. Toxicities were registered at each follow-up medical examination, and classified in accord with the Common Terminology Criteria for Adverse Events. Results: Twenty-four (53.3\%) patients presented the GG genotype ; 19 (42.2\%) the GT, and 2 (4.4\%) the TT. The AI treatment was Anastrazole for 35 patients (77.8\%) and Letrozole for the others (n=10 ; 22.2\%). Osteoporosis was significantly associated with the GG genotype (p=0.001). Treatment discontinuation (TD) was observed in 6 cases (13.3\%). The only parameter able to predict TD was the appearance of severe arthralgia/myalgia (Odds Ratio, OR=23.75 ; p=0.009), when adjusted for age and AI treatment. Conclusion: Our results suggest that CYP19A1 polymorphic variants may influence susceptibility to develop AI-related side effects. Further prospective studies are needed to confirm the role of the aromatase gene (CYP19A1) polymorphisms in predicting adverse effects to AI-based therapy. ; 1 ; FEB ; 10-14 ; 48 |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| العلاقة: | EURASIAN JOURNAL OF MEDICINE; https://hdl.handle.net/11443/1969Test; http://dx.doi.org/10.5152/eurasianjmed.2015.008Test; WOS:000373481300004 |
| DOI: | 10.5152/eurasianjmed.2015.008 |
| الإتاحة: | https://doi.org/10.5152/eurasianjmed.2015.008Test https://hdl.handle.net/11443/1969Test |
| رقم الانضمام: | edsbas.9CC5C878 |
| قاعدة البيانات: | BASE |
| DOI: | 10.5152/eurasianjmed.2015.008 |
|---|